SCHEMBL5227409

SCHEMBL5227409

CN1C(=O)c2ccncc2C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.56
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
CASP3 P42574 1/20 0.48
CYP3A4 P08684 4/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2C9 P11712 1/20 0.48
LMNA P02545 1/20 0.48
TSHR P16473 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP1A2 P05177 1/20 0.47
GAA P10253 1/20 0.47
CDC25B P30305 1/20 0.47
MAPT P10636 4/20 0.45
HSD17B10 Q99714 2/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14806780 0.86 NPSR1 (0.45) NPSR1KDM4EALDH1A1SMN1; SMN2MAOA
SCHEMBL23444278 0.80 NPSR1 (0.54) NPSR1KDM4EALDH1A1SMN1; SMN2MAOA
SCHEMBL21449885 0.80 NPSR1 (0.50) NPSR1KDM4EALDH1A1SMN1; SMN2MAOA
SCHEMBL21852716 0.80 NPSR1 (0.50) NPSR1KDM4EALDH1A1SMN1; SMN2MAOA
SCHEMBL12187917 0.79 NPSR1 (0.58) NPSR1KDM4EALDH1A1SMN1; SMN2MAOA
SCHEMBL11865351 0.79 ALDH1A1 (0.50) NPSR1KDM4EALDH1A1SMN1; SMN2MAOA
SCHEMBL11930015 0.79 NPSR1 (0.46) NPSR1KDM4EALDH1A1SMN1; SMN2MAOA
SCHEMBL9217368 0.78 NPSR1 (0.60) NPSR1KDM4EALDH1A1CYP3A4CYP2C19
SCHEMBL14560537 0.75 NPSR1 (0.57) NPSR1KDM4EALDH1A1CYP3A4CYP2C19
SCHEMBL2474607 0.75 TTR (0.55) NPSR1KDM4EALDH1A1SMN1; SMN2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022133551-A1 HISTONE DEACETYLASE INHIBITORS THE UNIVERSITY OF QUEENSLAND (AU) 2022-06-30 WO disclosed
EP-3831824-A1 PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) 2021-06-09 EP disclosed
EP-2978820-B1 WAVELENGTH CONVERSION FILMS WITH MULTIPLE PHOTOSTABLE ORGANIC CHROMOPHORES NITTO DENKO CORP (JP) 2018-03-21 EP disclosed
EP-2788450-B1 WAVELENGTH CONVERSION MATERIAL AS ENCAPSULANT FOR SOLAR MODULE SYSTEMS TO ENHANCE SOLAR HARVESTING EFFICIENCY NITTO DENKO CORP (JP) 2017-06-21 EP disclosed
US-9399730-B2 Wavelength conversion material as encapsulate for solar module systems to enhance solar harvesting efficiency NITTO DENKO CORPORATION (JP) 2016-07-26 US disclosed
US-9394479-B2 Wavelength conversion film having pressure sensitive adhesive layer to enhance solar harvesting efficiency NITTO DENKO CORPORATION (JP) 2016-07-19 US disclosed
US-9382424-B2 Highly-fluorescent and photo-stable chromophores for enhanced solar harvesting efficiency NITTO DENKO CORPORATION (JP) 2016-07-05 US disclosed
US-20160108310-A1 WAVELENGTH CONVERSION FILMS WITH MULTIPLE PHOTOSTABLE ORGANIC CHROMOPHORES NITTO DENKO CORPORATION (JP) 2016-04-21 US disclosed
US-20150041052-A1 WAVELENGTH CONVERSION LAYER ON A GLASS PLATE TO ENHANCE SOLAR HARVESTING EFFICIENCY NITTO DENKO CORPORATION (JP) 2015-02-12 US disclosed
US-20150041042-A1 PRESSURE SENSITIVE ADHESIVE TYPE OF WAVELENGTH CONVERSION TAPE FOR ENHANCING SOLAR HARVESTING EFFICIENCY NITTO DENKO CORPORATION (JP) 2015-02-12 US disclosed
US-RE38524-E1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2004-06-01 US disclosed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US disclosed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US disclosed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US disclosed
US-6525047-B2 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair PFIZER INC. 2003-02-25 US disclosed
US-6433171-B1 FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2002-08-13 US disclosed
US-6432945-B1 Dipeptide derivatives PFIZER INC. 2002-08-13 US disclosed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US disclosed
US-6251902-B1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2001-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR NPSR1 554/4885KDM4E 4543/4885ALDH1A1 3158/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR NPSR1 287/4885KDM4E 4596/4885ALDH1A1 3934/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR NPSR1 379/4885KDM4E 4540/4885ALDH1A1 3986/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR NPSR1 414/4885KDM4E 4247/4885ALDH1A1 3126/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR NPSR1 287/4885KDM4E 4596/4885ALDH1A1 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.